List of Equipment Companies in Sweden - 3

ArgusEye provides innovative sensor systems based on nanoplasmonic detection for real-time monitoring of biological systems and processes.

Mentice, founded in 1999 and based in Sweden, is a leader in medical simulation solutions focused on image-guided interventional therapies (IGIT). The company has transitioned from providing endovascular simulators to offering comprehensive IGIT performance solutions aimed at enhancing clinical outcomes through advanced training and procedural optimization. Mentice is publicly traded on Nasdaq First North Growth Market under the ticker MNTC. The company provides a range of software and hardware simulation solutions designed to improve clinical performance in minimally invasive procedures. Key products include the VIST® series of haptic-enabled simulators for vascular procedures and MIST® systems for basic endovascular training. Mentice also offers portable platforms and integrated performance solutions that optimize workflow and assess clinician competency. The use of haptic feedback technology allows for realistic training in complex interventions. Mentice collaborates with global medical device companies and healthcare institutions, including notable partnerships with Terumo and Abbott. The company aims for significant annual sales growth and has expanded its geographic reach, including establishing an office in Chicago. Mentice is committed to addressing the demand for safer and more efficient minimally invasive procedures.

Xspray Pharma (Nasdaq Stockholm: XSPRAY) aims to improve patients' quality of life by developing and producing pharmaceuticals, based on world leading technology and deep industry expertise. Xspray Pharma uses its innovative, patented, and scalable technology to develop improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The company has several product candidates in clinical development and a wide pipeline of potential candidates. The proven HyNap technology allows the company to gain entry before the secondary patents expire and can thereby benefit patients rapidly. Xspray Pharma's first product XS0004 dasatinib is pending FDA approval and has received orphan drug status in the US. Xspray Pharma's management team has extensive experience from the pharmaceutical industry. The company is based in Stockholm and shares are traded on Nasdaq Stockholm. www.xspraypharma.com